| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
| 2 | Nanoparticles in Photodynamic Therapy | Chemical Reviews | 2015 | 2,342 |
| 3 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | Nature | 2016 | 1,760 |
| 4 | The landscape of cancer genes and mutational processes in breast cancer | Nature | 2012 | 1,535 |
| 5 | The Simons Genome Diversity Project: 300 genomes from 142 diverse populations | Nature | 2016 | 1,216 |
| 6 | Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Nature | 2011 | 1,127 |
| 7 | Nasopharyngeal carcinoma | Lancet, The | 2016 | 1,045 |
| 8 | Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors | Nature Genetics | 2017 | 849 |
| 9 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) | European Journal of Immunology | 2019 | 766 |
| 10 | Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma | Cancer Discovery | 2017 | 637 |
| 11 | Isolation and retrieval of circulating tumor cells using centrifugal forces | Scientific Reports | 2013 | 618 |
| 12 | Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations | Annals of Oncology | 2015 | 607 |
| 13 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Annals of Oncology | 2018 | 526 |
| 14 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial | Lancet Oncology, The | 2022 | 526 |
| 15 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) | Annals of Oncology | 2019 | 512 |
| 16 | Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells | Lab on A Chip | 2014 | 485 |
| 17 | Molecular landmarks of tumor hypoxia across cancer types | Nature Genetics | 2019 | 480 |
| 18 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer | Annals of Oncology | 2021 | 454 |
| 19 | Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms | Cancer Gene Therapy | 2021 | 444 |
| 20 | Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet Oncology, The | 2014 | 434 |
| 21 | Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers | Nature Genetics | 2013 | 426 |
| 22 | Redefining Palliative Care—A New Consensus-Based Definition | Journal of Pain and Symptom Management | 2020 | 423 |
| 23 | Biological response of cancer cells to radiation treatment | Frontiers in Molecular Biosciences | 2014 | 389 |
| 24 | Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil | Gastroenterology | 2013 | 381 |
| 25 | Genomic analyses inform on migration events during the peopling of Eurasia | Nature | 2016 | 360 |
| 26 | Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial | Journal of Clinical Oncology | 2020 | 355 |
| 27 | A recent bottleneck of Y chromosome diversity coincides with a global change in culture | Genome Research | 2015 | 348 |
| 28 | An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma | Cancer Cell | 2011 | 347 |
| 29 | Titania Coated Upconversion Nanoparticles for Near-Infrared Light Triggered Photodynamic Therapy | ACS Nano | 2015 | 331 |
| 30 | Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy | Cells | 2020 | 314 |
| 31 | Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy | Gastroenterology | 2011 | 304 |
| 32 | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study | Lancet Oncology, The | 2015 | 299 |
| 33 | Global diversity, population stratification, and selection of human copy-number variation | Science | 2015 | 293 |
| 34 | Genomic landscape of lung adenocarcinoma in East Asians | Nature Genetics | 2020 | 281 |
| 35 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 276 |
| 36 | Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) | Thoracic Cancer | 2020 | 275 |
| 37 | Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia | Science Translational Medicine | 2017 | 272 |
| 38 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families | Journal of Clinical Oncology | 2020 | 270 |
| 39 | Genomic insights into the peopling of the Southwest Pacific | Nature | 2016 | 262 |
| 40 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 260 |
| 41 | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study | Journal of Clinical Oncology | 2021 | 257 |
| 42 | Changing epidemiology of oral squamous cell carcinoma of the tongue: A global study | Head and Neck | 2017 | 253 |
| 43 | Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines | Radiotherapy and Oncology | 2018 | 244 |
| 44 | Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations | Journal of Clinical Oncology | 2022 | 242 |
| 45 | Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma | Cancer Discovery | 2012 | 236 |
| 46 | Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool | Science Translational Medicine | 2013 | 233 |
| 47 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo | Nature | 2017 | 229 |
| 48 | Methionine is a metabolic dependency of tumor-initiating cells | Nature Medicine | 2019 | 226 |
| 49 | Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations | Human Mutation | 2018 | 224 |
| 50 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study | Lancet Oncology, The | 2021 | 222 |
